SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
Safe and effective vaccines against SARS-CoV-2 were developed in less than 1 year.
|
9th Influenza Conference 2023
Scientific highlights of the 9th ESWI Influenza Conference
With promising developments in the field of respiratory viral infections, the conference sessions covered hot topics on seasonal, pandemic, and zoonotic influenza viruses, as well as other respiratory viruses such as RSV and SARS-CoV-2.
The hinge-engineered IgG1-IgG3 hybrid subclass IgGh47 potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies
Streptococcus pyogenes can cause invasive disease with high mortality despite adequate antibiotic treatments. To address this unmet need, we have previously generated an opsonic IgG1 monoclonal antibody, Ab25, targeting the bacterial M protein.
The influenza landscape and vaccination coverage in older adults during theSARS-Cov-2 pandemic: data from Several European Countries and Israel
While influenza and the common cold are both contagious viral respiratory tract illnesses, influenza can be a serious disease that could lead to severe complications and unfavorable outcomes due to broader consequences.
ECDC on Air podcast. Why Monitoring Respiratory Viruses Matters?
In this episode, ECDC expert on respiratory viruses, Nick Bundle, gives the lowdown on the European Respiratory Virus Surveillance Summary (ERVISS), a new surveillance tool which presents weekly data on influenza, SARS-CoV-2 and RSV.
In Utero Exposure to Maternal COVID-19 Vaccination and Offspring Neurodevelopment at 12 and 18 Months
Uptake of COVID-19 vaccines among pregnant individuals was hampered by safety concerns around potential risks to unborn children.
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant.
Perception of government performance during COVID-19 not linked to death rate.
People living in the United States are more likely to report that their government handled the COVID-19 pandemic ‘well’ than any other G7 nation despite having the highest death rate, according to a new report from the Global Listening Project.
Article
News
Scientific Papers
Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort
The protection of fourth dose mRNA vaccination against SARS-CoV-2 is relevant to current global policy decisions regarding ongoing booster roll-out.
Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults
Human infection challenge permits in-depth, early, and pre-symptomatic characterization of the immune response, enabling the identification of factors that are important for viral clearance.
WHO Information Network for Epidemics update on COVID-19
Latest information about circulation, impact and what is needed to prevent infections, severe disease, post-COVID-19 condition and deaths.
